Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Can Meet Mandatory Payment Deadlines, Exec Insists

This article was originally published in Scrip

Executive Summary

Buying back shares and debt is where Valeant Pharmaceuticals International Inc. sees return on investment in the short-term, the Jefferies 2015 Global Healthcare Conference in London heard on Nov. 18. Apparently there isn't enough cash available for large scale M&A but there will continue to be smaller "tuck in" deals, according to Laurie Little, senior vp of investor relations.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts